A drug once known almost exclusively for preventing organ transplant rejection is now at the center of a National Institute on Aging-funded clinical study at UT Health San Antonio, to determine how rapamycin should be used in older adults to promote healthy aging.

In its first appearance in the national standings as a united institution, UT San Antonio posted a strong performance in the latest rankings from the Blue Ridge Institute for Medical Research. The Blue Ridge Institute is an independent nonprofit organization that compiles annual funding data from the National Institutes of Health.